Brief assessment of cognition in immune effector cell-associated neurotoxicity syndrome
Abstract
Background
Immune-effector cell-associated neurotoxicity syndrome (ICANS) is a common acute adverse event of chimeric antigen T-cell (CAR–T) therapy associated with a range of neurological and cognitive symptoms. Recent evidence has highlighted that cognitive changes in ICANS may predate changes in the current standard cognitive screening instrument. This study aimed to develop a novel screening instrument sensitive to ICANS-related cognitive dysfunction.
Methods
Patients were administered a 21-item bedside cognitive screening instrument (the Neuropsychiatry Unit Cognitive Assessment Tool) followed by an inpatient neuropsychological assessment. A cognitive screening index was computed by summing the beside items that maximally differentiated between ICANS and non-ICANS patients. A separate neuropsychological index was also derived.
Results
Among the 50 patients included, 26 (52%) had ICANS at assessment. Six screening tests and five neuropsychological tests demonstrated acceptable clinical utility for indices computation (AUC>0.70). ICANS patients had lower scores on both the cognitive screening index (p<.001) and the neuropsychological index (p< .001) than non-ICANS patients. The cognitive screening index (AUC=0.80) and the neuropsychological index (AUC=0.81) achieved acceptable clinical utility. Although there was no significant difference between the AUCs of the two indices (p=.765), hierarchical logistic regression showed that the neuropsychological index improved the classification of ICANS patients (p<.05).
Conclusion
The cognitive screening index can reliably discriminate between ICANS and non-ICANS patients, but neuropsychological examination provides more detailed cognitive characterisation in ICANS. Further validation of the cognitive screening index will inform practice in this emerging area of clinical need.
Related articles
Related articles are currently not available for this article.